These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 36016128)
1. Increased Mild Vaccine-Related Side Effects and Higher Specific Antibody Titers in Health Care Workers with Previous SARS-CoV-2 Infection after the mRNA BNT162b2 Vaccine. Ferrari L; Compagno M; Campogiani L; Teti E; Mulas T; Checchi D; Alessio G; Caldara F; Coppola L; De Simone G; Ceccarelli L; Spalliera I; Vitale P; Grelli S; Andreoni M; Sarmati L; Iannetta M Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016128 [TBL] [Abstract][Full Text] [Related]
2. Bimodal antibody-titer decline following BNT162b2 mRNA anti-SARS-CoV-2 vaccination in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Isgrò MA; Trillò G; Russo L; Tornesello AL; Buonaguro L; Tornesello ML; Miscio L; Normanno N; Bianchi AAM; Buonaguro FM; Cavalcanti E; Infect Agent Cancer; 2022 Jul; 17(1):40. PubMed ID: 35902961 [TBL] [Abstract][Full Text] [Related]
3. Impact of prior infection status on antibody response to the BNT162b2 mRNA COVID-19 vaccine in healthcare workers at a COVID-19 referral hospital in Milan, Italy. Milazzo L; Pezzati L; Oreni L; Kullmann C; Lai A; Gabrieli A; Bestetti G; Beschi C; Conti F; Ottomano C; Gervasoni C; Meroni L; Galli M; Antinori S; Ridolfo AL Hum Vaccin Immunother; 2021 Dec; 17(12):4747-4754. PubMed ID: 35086438 [TBL] [Abstract][Full Text] [Related]
4. Differences in SARS-CoV-2-Specific Antibody Responses After the First, Second, and Third Doses of BNT162b2 in Naïve and Previously Infected Individuals: A 1-Year Observational Study in Healthcare Professionals. Ogrič M; Žigon P; Podovšovnik E; Lakota K; Sodin-Semrl S; Rotar Ž; Čučnik S Front Immunol; 2022; 13():876533. PubMed ID: 35711413 [TBL] [Abstract][Full Text] [Related]
5. Vaccination strategy and anti - SARS-CoV-2 S titers in healthcare workers of the INT - IRCCS "Fondazione Pascale" Cancer Center (Naples, Italy). Cavalcanti E; Isgrò MA; Rea D; Di Capua L; Trillò G; Russo L; Botti G; Miscio L; Buonaguro FM; Bianchi AAM Infect Agent Cancer; 2021 May; 16(1):32. PubMed ID: 33980271 [TBL] [Abstract][Full Text] [Related]
6. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study. Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD; Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524 [TBL] [Abstract][Full Text] [Related]
7. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine. Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR Front Immunol; 2022; 13():827306. PubMed ID: 35173736 [TBL] [Abstract][Full Text] [Related]
8. Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection. Israel A; Shenhar Y; Green I; Merzon E; Golan-Cohen A; Schäffer AA; Ruppin E; Vinker S; Magen E Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062724 [TBL] [Abstract][Full Text] [Related]
9. Boosting maternal and neonatal humoral immunity following SARS-CoV-2 infection using a single messenger RNA vaccine dose. Nevo L; Cahen-Peretz A; Vorontsov O; Frenkel R; Kabessa M; Cohen SM; Hamrani A; Oiknine-Djian E; Lipschuetz M; Goldman-Wohl D; Walfisch A; Kovo M; Neeman M; Yagel S; Wolf DG; Beharier O Am J Obstet Gynecol; 2022 Sep; 227(3):486.e1-486.e10. PubMed ID: 35430228 [TBL] [Abstract][Full Text] [Related]
10. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections. Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G Front Immunol; 2022; 13():863554. PubMed ID: 35711445 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668 [TBL] [Abstract][Full Text] [Related]
12. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection. Israel A; Shenhar Y; Green I; Merzon E; Golan-Cohen A; Schäffer AA; Ruppin E; Vinker S; Magen E medRxiv; 2021 Aug; ():. PubMed ID: 34462761 [TBL] [Abstract][Full Text] [Related]
13. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.]. Casas Fischer R Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347 [TBL] [Abstract][Full Text] [Related]
14. Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. Tanaka H; Mukai J; Kushibiki K; Mizushima S; Maeda K; Fujimoto Y; Sawada R; Oda M; Okuda H; Yamaki M; Hashiguchi S; Kawai I; Kawaguchi I; Masuda N; Matsushita H Vaccine; 2023 Jan; 41(2):365-371. PubMed ID: 36460533 [TBL] [Abstract][Full Text] [Related]
15. Antibody Response after BNT162b2 Vaccination in Healthcare Workers Previously Exposed and Not Exposed to SARS-CoV-2. Salvaggio M; Fusina F; Albani F; Salvaggio M; Beschi R; Ferrari E; Costa A; Agnoletti L; Facchi E; Natalini G J Clin Med; 2021 Sep; 10(18):. PubMed ID: 34575315 [TBL] [Abstract][Full Text] [Related]
16. Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in Japan. Matsuura T; Fukushima W; Nakagama Y; Kido Y; Kase T; Kondo K; Kaku N; Matsumoto K; Suita A; Komiya E; Mukai E; Nitahara Y; Konishi A; Kasamatsu A; Nakagami-Yamaguchi E; Ohfuji S; Kaneko Y; Kaneko A; Kakeya H; Hirota Y Vaccine; 2022 Sep; 40(38):5631-5640. PubMed ID: 36028457 [TBL] [Abstract][Full Text] [Related]
17. Decline of Anti-SARS-CoV-2 IgG Antibody Levels 6 Months after Complete BNT162b2 Vaccination in Healthcare Workers to Levels Observed Following the First Vaccine Dose. Đaković Rode O; Bodulić K; Zember S; Cetinić Balent N; Novokmet A; Čulo M; Rašić Ž; Mikulić R; Markotić A Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214612 [TBL] [Abstract][Full Text] [Related]
18. Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study. Buonfrate D; Piubelli C; Gobbi F; Martini D; Bertoli G; Ursini T; Moro L; Ronzoni N; Angheben A; Rodari P; Cardellino C; Tamarozzi F; Tais S; Rizzi E; Degani M; Deiana M; Prato M; Silva R; Bisoffi Z Clin Microbiol Infect; 2021 Dec; 27(12):1845-1850. PubMed ID: 34329793 [TBL] [Abstract][Full Text] [Related]
19. Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity. Kara Z; Akçin R; Demir AN; Dinç HÖ; Taşkın HE; Kocazeybek B; Yumuk VD Obes Surg; 2022 Sep; 32(9):2987-2993. PubMed ID: 35802279 [TBL] [Abstract][Full Text] [Related]
20. Longitudinal Dynamics of SARS-CoV-2 IgG Antibody Responses after the Two-Dose Regimen of BNT162b2 Vaccination and the Effect of a Third Dose on Healthcare Workers in Japan. Sakamoto A; Yoshimura M; Itoh R; Ozuru R; Ishii K; Sechi Y; Nabeshima S; Hiromatsu K Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746438 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]